The official blog of the Lung Institute.

Stem Cell Research Study vs. Treatment

25 May 2015
| Under COPD, Treatments | Posted by | 0 Comments
Treatment Vs Study Lung Institute Lung Institute

The Difference Between a Research Study and a Treatment

The Lung Institute is poised to open its fourth clinic in Pittsburgh, Pennsylvania in July of 2015. However, stem cell research, and even pulmonary care, is not new to the Pittsburgh region. The University of Pittsburgh Medical Center has been ranked among the best facilities for pulmonary disease treatment and research in the nation, and the University of Pittsburgh McGowan Institute for Regenerative Medicine has been conducting stem cell research since 1992.  This has opened the floor for a lot of questions as to why someone may elect to choose a stem cell research study versus stem cell treatment for lung disease.

Pros and Cons of a Research Study vs. Treatment

There are many benefits to both research studies and direct treatments. Studies offer cutting-edge information while collecting and providing data that will eventually help the medical community create more innovative treatments. Direct treatments help patients breathe easier today by applying lessons learned through years of medical practice. Inevitably, it comes down to the patient. Do you feel like a study, which will provide you with a 50 percent chance of receiving the tested medication, is acceptable for the state of your condition? Some may say yes, but those with a chronic, debilitating lung disease that is terminal and incurable, would likely say no.

The Bridge to a Cure for COPD

There is no cure for chronic obstructive pulmonary disease (COPD) or interstitial lung disease. Due to the nature of the diseases, they will continue to progress, worsen and eventually attribute to the death of the patient. The question lies in when a cure will be available. With advances in some medications like Ofev and Pirfenidone, and the ability for stem cell therapy to help improve lung function, many people feel that a cure is on the horizon. Even if it is five, ten or twenty years away, patients that are suffering today need to be able to survive until that day comes.

In the end, a research study may include the next big advancement in the treatment of COPD, but test subjects only have a 50 percent chance of getting that drug (with the other half only receiving a placebo); in addition to the likelihood of the drug working, the chance for a test subject’s lung function to improve is often slim. If a study is researching a drug that actually performed and, by some miracle, had a 100 percent success rate among the patients that got the drug, only 50 percent of the test subjects would see that relief. This number reflects a 20 percent drop from those that see relief from stem cell therapy at the Lung Institute.

Of course, there is an overwhelming need for continued clinical studies dealing with stem cell therapy, but for those who need an option today, the Lung institute is here to help. If you or a loved one suffers from a lung disease, contact us today at (800) 729-3065 to see if you qualify.

Your Comment

Your email address will not be published.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.